Effects of antidepressant drugs on a quickly-learned conditioned-suppression response in mice.
Mice experienced to electric shock, exhibited a marked suppression of motor activity when placed in the same cage 24 hr after administration of shocks. Acute administration of imipramine-HCl (10 mg/kg, i.p.), desipramine-HCl (5 and 10 mg/kg, i.p.) and amitriptyline-HCl (5 and 10 mg/kg, i.p.) caused marked reduction of the conditioned suppression of shocked mice, but reduced the motor activity of the non-shocked mice. Maprotiline, mianserin and dimetacrine did not cause reduction of the conditioned suppression. Nialamide (100 mg/kg, i.p.) and pargyline-HCl (100 and 200 mg/kg, i.p.) caused marked reduction of the conditioned suppression but did not increase the motor activity of the non-shocked mice, and tranylcypromine-HCl (10 and 20 mg/kg, i.p.) did not cause reduction of the conditioned suppression. Diphenhydramine-HCl (10 and 20 mg/kg, i.p.) reduced the conditioned suppression of shocked mice in a dose-related manner. Chronic administration of imipramine-HCl (1 and 5 mg/kg, i.p.) for 14 days significantly reduced the conditioned suppression but did not influence the motility rate of the non-shocked mice. Also, chronic administration of amitriptyline (1 mg/kg, i.p.), desipramine (5 mg/kg, i.p.) and dimetacrine (10 mg/kg, i.p.), for 10 days, significantly reduced the conditioned suppression, but did not influence the motility rate of the non-shocked mice. Chronic administration of maprotiline reduced the conditioned suppression. On the other hand, chronic administration of mianserin (5 mg/kg, i.p.) and diphenhydramine (10 mg/kg, i.p.) did not cause a reduction of the conditioned suppression.
D000166:Acridines / Q000627:therapeutic use; D000639:Amitriptyline / Q000627:therapeutic use; D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy*; D003891:Desipramine / Q000627:therapeutic use; D004155:Diphenhydramine / Q000627:therapeutic use; D004195:Disease Models, Animal; D004597:Electroshock; D000431:Ethanol / Q000627:therapeutic use; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008297:Male; D008376:Maprotiline / Q000627:therapeutic use; D008803:Mianserin / Q000627:therapeutic use; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009526:Nialamide / Q000627:therapeutic use; D010293:Pargyline / Q000627:therapeutic use; D014191:Tranylcypromine / Q000627:therapeutic use
D000166:Acridines; D000928:Antidepressive Agents; D000639:Amitriptyline; D008803:Mianserin; D008376:Maprotiline; D014191:Tranylcypromine; D000431:Ethanol; D004155:Diphenhydramine; D010293:Pargyline; C100110:dimethacrine; D007099:Imipramine; D009526:Nialamide; D003891:Desipramine